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CHAPTER I: Introduction 
Concept of specific inhibition of extrinsic coagulation cascade 
Hemostasis, the physiological response to vascular injury, results in the formation of 
a hemostatic plug that prevents blood loss. Under normal conditions, factors that 
promote blood coagulation are balanced by those that inhibit it. Pathologic thrombosis 
occurs when procoagulant stimuli overwhelm natural anticoagulant and fibrinolytic 
systems. Such stimuli include vessel wall damage, inflammation, stasis and the 
excessive activation of coagulation. Damage to the vascular wall and the resultant 
exposure of tissue factor (TF)-expressing cells to blood initiate coagulation in both the 
arteries and veins [1]. Inflammatory cytokines generated after trauma, surgery, or 
medical illness can contribute to the procoagulant state. Endothelial cells are activated 
by inflammatory cytokines and express adhesion molecules that tether leukocytes to 
their surface. Bound monocytes produce TF and express the receptors for factor X and 
fibrinogen, and they promote coagulation [2, 3]. There are many reports that 
atherosclerotic plaques contain tissue factor, which is expressed by macrophages, 
smooth muscle cells and endothelial cells [4, 5]. TF was also seen in the lipid-rich core 
of atheromas, apparently associated with highly procoagulant microparticles derived 
from apoptotic cells, activated platelet and inflammatory cell [1]. Oxidized cholesterol 
and elevated glucose level can also induce TF expression and statins are known to lower 
TF levels by long-term treatment. This TF in pathogenic states is functionally active and 
competent to elicit thrombus formation when exposed to flowing blood. Venous thrombi 
develop under low-flow conditions and usually originate in the muscular veins of the 
calf or in the valve cusps pockets of the deep calf vein. Because the venous valve cusps 
are avascular, they depend on the circulating blood for their oxygen and nutrient supply. 
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Local hypoxemia occurs with venous stasis and can induce TF expression in the valve 
cusps. Also a high risk for venous thrombosis is considered to be partially due to 
TF-containing microparticle release during tissue damage. In addition to these etiology 
results for TF, epidemiological analysis shows that high plasma levels of factor VIIa 
(FVIIa) correlate with high morbidity of coronary heart disease (CHD) and myocardial 
infarction (MI) [6]. Some genome wide association studies indicate that FVIIa levels are 
changed by R353Q polymorphism [7] and that FVII ins-323 allele decreases the 
frequency of stroke in atrial fibrillation (AF) patients [8]. Also the CHD events lowering 
effect due to statins is known to be affected by FVII SNPs [9]. 
Since it is generally accepted that thrombus formation is initiated by TF in vivo [1], 
drugs that target the TF/VIIa complex should be potent anticoagulants. Theoretically, 
either inhibition of TF/VIIa complex formation or inhibition of its active-site which is 
responsible for cleavage of mainly factor X will disable the extrinsic coagulation 
pathway (Fig.1).  
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Fig.1. Blood coagulation cascade and mechanism of action for achieving extrinsic 
coagulation specific inhibition 
  
3
Confidential
XII→XIIa
XI→→XIa
Ca++
TF
VIIIa
↑
↑
VIII
Prothrombin
Thrombin
FibrinogenFibrin
Va
↑
V
XIII
↓
XIIIa
Intrinsic Pathway
(aPTT)
Extrinsic Pathway
(PT)
Xa Ca++
Ca++
Initiation
Propagation
Fibrin formation
VII
XIX TF/VIIa
IXa
×
Ex. Dabigatran
Ex. Rivaroxaban
Apixaban
ER-410660
5 
 
The intensive search for novel anticoagulants reflects the significance and impact on 
the healthcare system of both thrombosis and its prevention. Antithrombotics are needed 
for short-term use in the setting of acute medical conditions, and also for the long-term 
prevention of thrombotic events. While for short-term use, parenteral administration of 
drugs is most desirable, oral administration is the goal for long-term medication. 
Considering also the major concern of anticoagulation, i.e. bleeding complications, an 
ideal antithrombotic drug should fulfill the following requirements. 
 
 good intestinal absorption 
 adequate plasma protein binding 
 appropriate half-life with a duration giving good compromise between 
convenience and safety 
 predictable pharmacokinetic and pharmacodynamic profiles with rapid onset 
 no need for anticoagulation activity monitoring  
 no food or drug interactions 
 no risk of thrombocytopenia 
 a reversible action 
 
Many companies are focusing on the development of direct and selective coagulation 
inhibitors that attempt to fulfill the requirements mention above [1, 10, 11]. New 
anticoagulant strategies have targeted blocking the initiation step, preventing the 
propagation step, or inhibiting thrombin. The initiation step can be stopped by agents 
that affect the TF/VIIa complex, whereas the propagation step can be blocked by drugs 
that inhibit factor IXa or factor Xa. Finally, thrombin inhibitors prevent fibrin formation 
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and block thrombin-mediated feedback activation. There are many candidate drugs that 
target thrombin and factor Xa, for example dabigatran, rivaroxaban, apixaban, edoxaban, 
betrixaban and YM150 have progressed to clinical testing [12, 13]. The front-running 
oral agent is dabigatran [14, 15], rivaroxaban [16, 17, 18], and apixaban [19] which has 
entered the global markets for prevention of venous thromboembolism and 
cardioembolic stroke. It has become obvious that excessive inhibition of factors 
common to both coagulation pathways can lead to bleeding complications. On the other 
hand, TF/VIIa complex inhibitors may prove to be enhanced antithrombotic drugs with 
decreased bleeding risk, because they leave intact the intrinsic pathway, so maintaining 
normal hemostasis. Although TF/VIIa complex is a proper and attractive target, only a 
few parenteral drugs that target this complex have been evaluated in clinical trials [1, 4, 
21-30]. These include anti-TF antibody [4, 21, 26], recombinant tissue factor pathway 
inhibitor (TFPI) [1, 4, 22], active-site blocked factor VIIa (FVIIai) [1, 4] and nematode 
anticoagulant peptide (rNAPc2) [27-29]. NAPc2 is isolated from the saliva of the 
hookworm Ancylostoma caninum and interferes with TF activity by binding to factor Xa 
or factor X to form an inhibitory complex with TF/VIIa. Several studies in primates, as 
well as first studies in human revealed very promising results in a phase II clinical trial, 
which were that rNAPc2 indeed appeared safe and effective in preventing overall 
postoperative venous thromboembolism in patients undergoing total knee replacement, 
and inhibited thrombin generation during coronary angioplasty. However, all the 
development programs of rNAPc2 including those for cancer were terminated by 
Nuvelo due to the company’s present financial problems. Furthermore, the development 
of a small molecule, direct TF/VIIa active-site inhibitor as an oral anticoagulant has yet 
to be achieved [30]. 
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Epidemiology of antithrombotic drug market 
The cardiovascular market is the biggest segment of the pharmaceutical market. In 
2002, sales of cardiovascular products exceeded $50 billion and accounted for nearly 
20 % of prescription pharmaceutical sales in the seven major markets (United States, 
France, Germany, Italy, Spain, United Kingdom and Japan). This market comprises five 
clearly defined segments, of which antithrombotics constitute the third-largest (about 
13 %), and the only one that has grown at a rate similar to the antidyslipidemic segment. 
In the United States, the anticoagulant market has grown at 18 % per year and the 
antiplatelet market at 34 % per year. Antithrombotic agents are used for the treatment of 
a number of major cardiovasucular conditions, including acute ischemic stroke, acute 
myocardial infarction, atrial fibrillation, venous thrombosis/pulmonary embolism and 
unstable angina. Epidemiology of select cardiovascular conditions in the major markets 
is provided in the table below. 
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Tabale 1  Epidemiology of select cardiovascular conditions in the major 
markets 
 
  
          
Source: Decision Resources, Inc
2002 2007 2012 2002-2012
(000s) % (000s) % (000s) % Growth (%/year)
Acute ischemic stroke
Events 1357.0 1478.6 1625.6 1.8
Diagnosed (% of total) 1154.7 85.1 1302.1 88.1 1464.3 90.1 2.4
Acute myocardial infarction
Events 729.8 786.9 857.1 1.6
Diagnosed (% of total) 729.8 100 786.9 100 857.1 100 1.6
Atrial fibrillation
Events 7412.0 7963.8 8616.5 1.5
Diagnosed (% of total) 5772.4 77.9 6488.3 81.5 7021.6 81.5 2
Venous thrombosis/pulmonaru embolism
Events 1190.8 1280.8 1382.8 1.5
Diagnosed (% of total) 1190.7 100 1280.8 100 1382.8 100 1.5
Unstable angina/non-ST-elevation myocardial infarction
Events 2762.9 2985.5 3250.1 1.6
Diagnosed (% of total) 2762.9 100 2985.5 100 3250.1 100 1.6
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Atrial fibrillation is generally treated with oral antiplatelet agents, principally aspirin 
for low-risk patients and anticoagulants for patients at greater risk. Acute ischemic 
stroke is treated symptomatically with oral agents. Acute myocardial infarction is 
treated with a variety of antithrombotic agents. Oral antiplatelet agents are used both 
during treatment and subsequently for prophylaxis, while intravenous therapeutics of 
various classes are used in the acute setting. Patients with a significant risk of 
developing venous thrombosis are generally treated with anticoagulants, and usually for 
prolonged periods, with intravenous agents widely used after major surgery. Unstable 
angina is generally treated prophylactically with oral agents, the use of intravenous 
therapies being confined to the acute setting. 
The $17 billion antithrombotics market has maintained consistent growth over the 
2004-2008 period in seven major markets (US, Japan, France, Germany, Italy and UK). 
Among the antithrombotics market, the value sales of anticoagulants have grown as 
well as that of antiplatelets. 
[Antithrombotics: Will Generics Temper the Strong Sales Trend? Spectrum: 2004] 
 
Trend in medical care and treatment for target diseases 
Outline of current treatment for thromboisis 
Thrombosis can occur in either the arterial or venous circulation. With respect to the 
arteries, most heart attacks and many strokes are triggered by thrombosis secondary to 
disrupted atherosclerotic plaques. Atrial fibrillation is another cause of stroke. Patients 
with this common rhythm abnormality have a five-fold greater risk of having a stroke 
because of their propensity for left atrial thrombosis and subsequent cerebral embolism. 
Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary 
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embolism and is the third most common vascular disorder after heart attack and stroke. 
In contrast to arterial thrombosis, venous thrombi usually arise in areas where the vein 
wall is grossly intact. Sluggish blood flow, endothelial cell activation, and 
hypercoagulability predispose patients to DVT. 
Thrombi are composed of platelet aggregates, fibrin and trapped red cells. Because 
arterial thrombi form under high-shear conditions, platelets are abundant and fibrin is 
relatively sparse. In contrast, venous thrombi, which form under low-shear conditions, 
are rich in fibrin and trapped red cells and contain fewer platelets. These features have 
important implications for antithrombotic therapy. Targeting the components of both 
arterial and venous thrombi, antithrombotic drugs encompass antiplatelet agents, 
anticoagulants, and fibrinolytic drugs. Because of the preponderance of platelets in 
arterial thrombi, antiplatelet drugs are the mainstay of their prevention and treatment. 
However, anticoagulants are also effective in this setting, although they are not widely 
used. Anticoagulants are the mainstay in the prevention and treatment of VTE because 
fibrin predominates in venous thrombi. Antiplatelet drugs are less efficacious than 
anticoagulants in reducing the risk of VTE, which is consistent with the scarcity of 
platelets in venous thrombi. 
Despite the widespread use of antithrombotic drugs, thrombotic diseases continue to 
be a major cause of death and disability. Therefore, there remains a need for more 
effective therapies to combat these disorders. 
 
Unmet medical needs in treatment with warfarin 
Stroke prevention in patients with atrial fibrillation and prevention of recurrence in 
patients with unprovoked VTE require long-term anticoagulant therapy. For the past 65 
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years, the only oral anticoagulants that have been available are the vitamin K 
antagonists, such as warfarin. Although effective, warfarin has many limitations as 
follows. 
 
Limitations Consequences 
Slow onset of action 
Necessitates overlap with rapidly 
acting parenteral anticoagulants 
Genetic polymorphisms affect 
metabolism 
Variable dose requirements 
Multiple food and drug interactions Coagulation monitoring required 
Narrow therapeutic window Coagulation monitoring required 
 
Because of these inconveniences, many patients with atrial fibrillation refuse to take 
anticoagulant therapy, thereby forgoing an opportunity for stroke prevention. Even 
when patients do take warfarin, therapeutic levels of anticoagulation are achieved only 
half the time. These problems highlight the need for more convenient oral anticoagulant 
drugs that can be given in fixed doses and will produce a predictable anticoagulant 
response such that little or no monitoring is required. 
An overarching problem with antithrombotic therapy is the difficulty of striking the 
optimal balance between efficacy and safety, particularly bleeding. There is mounting 
evidence that bleeding is associated with adverse cardiovascular outcomes and carries 
the same risk of mortality that recurrent ischemia does. The adverse impact of bleeding 
has prompted an evaluation of antithrombotic regimens that maximize efficacy without 
increasing the risk of bleeding and highlighted the need for antithrombotic drugs that 
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attenuate thrombosis with minimal effects on hemostasis. Only by identifying new drug 
targets, these closely linked biological processes are likely to be separated. 
 
Novel Anticoagulants 
The greatest unmet medical need in anticoagulant therapy is a simple and convenient 
replacement for warfarin to streamline long-term treatment. Most of the attention has 
focused on the development of oral agents that target thrombin or factor Xa. However, 
the utility of a long-acting synthetic parenteral pentasaccharide, which also targets 
factor Xa, is under investigation. 
 
Thrombin inhibitors 
As the final effector in coagulation, thrombin converts fibrinogen to fibrin. Thrombin 
also amplifies its own generation by feedback activation of factors V and VIII, 
respectively. In addition, thrombin coordinates the process of platelet activation and 
aggregation with coagulation. Because of its multiple roles in coagulation, the inhibition 
of thrombin not only blocks fibrin formation but also attenuates thrombin generation 
and platelet activation. 
The suitability of thrombin as a target was validated by clinical experience with 
ximelagatran, the first oral, direct thrombin inhibitor. Ximelagatran was shown to be not 
inferior to conventional anticoagulants for prevention and treatment of VTE and for 
stroke prevention in atrial fibrillation. Ximelagatran was withdrawn because of potential 
hepatotoxicity, but the favorable results with this drug confirmed long-term thrombin 
inhibition as an effective and safe strategy, at least with regard to the hemorrhage 
problem. 
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Factor Xa inhibitors 
When factor Xa is assembled along with factor Va on the surface of activated 
platelets, the resultant prothrombinase complex is a potent activator of prothrombin. 
Consequently, inhibitors of factor Xa block thrombin generation. The orally 
administered factor Xa inhibitors are small molecules that bind to the active site of 
factor Xa in a reversible fashion. As a class, these drugs have high oral bioavailability, a 
rapid onset of action, half-lives that range from 7 to 15 h, and both renal and extrarenal 
mechanisms of excretion. Although direct comparisons of orally active inhibitors of 
factor Xa and of thrombin in animal models have suggested that, for similar 
antithrombotic efficacy, upstream inhibition at the level of factor Xa causes less 
bleeding than downstream blockade of thrombin, head-to-head trials in humans have 
not been performed. Nonetheless, in phase II trials, dose-dependent increases in the 
rates of bleeding are observed with inhibitors of either factor Xa or thrombin. Therefore, 
at this point, there is no evidence that one target is any better than the other. 
 
Consequence 
As the potential advantages of the new anticoagulants over warfarin, the new agents 
have been designed to be administered in fixed doses without the need for routine 
coagulation monitoring. This is possible because these agents are not affected by any 
food constituents and the potential for drug-drug interactions is low. It is forecasted that 
value sales of anticoagulants market will continue to grow in the next decade. Currently 
launched products and pipeline compounds are expected to lead the anticoagulants 
market. Rivaroxaban and dabigatran replacing enoxaparin are seen as the next 
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blockbusters in the anticoagulants market. In the search result from the published 
database, PCI-27483 (Pharmacyclics) alone is once being clinically developed (Ph I) as 
a small compound TF/VIIa inhibitor by subcutaneous administration. But, the 
development of PCI-27483 was frozen at this moment, though the reason is not obvious. 
So TF/VIIa inhibitors are thought to be an unexplored field of anticoagulants at this 
time. In the future, new products with varied MOA related to coagulation factors are 
expected to be marketed. TF/VIIa inhibitors will be evaluated in comparison with them 
in addition to warfarin from the viewpoints of efficacy, safety and convenience in the 
prevention or treatment of thrombosis. 
[Keiser J, Vascular Pharmacology: Opportunities for Intervention. Clin Pharmacol Ther, 
2009;86,139-46] 
 
Target indications and populations 
Venous thrombosis and pulmonary embolism 
Deep vein thrombosis and pulmonary embolism (DVT/PE) represent a major public 
health problem. A 25-year population-based study published in 1998 found that the 
overall age- and sex-adjusted annual incidence of VTE was 1.17 per 1,000 (0.48 per 
1,000 for DVT and 0.69 per 1,000 for PE). Applying these figures to today’s population 
of approximately 300 million Americans suggests that more than 350,000 individuals 
are affected by DVT/PE each year [31]. But there is reason to believe that the true 
incidence rate could be significantly higher. Several studies suggest that these diseases 
are often undiagnosed. Some study of nursing home patients found that the condition 
was correctly diagnosed before death in only 39 to 50 % of patients where it was 
confirmed in an autopsy. Therefore as many as 700,000 cases of DVT/PE may occur in 
US each year. A 20-year review of data found that the age-adjusted death rate for PE 
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was 94 per 1,000,000 individuals. Extrapolating to today’s US population suggests that 
an estimated 28,200 people die in each year. But as noted previously, PE is often 
undiagnosed, and thus the true death rate is almost certainly substantially higher. It is 
estimated that 30 % of patients will die within 3 months. Applying this 30 % figure to 
the previously estimation of 700,000 cases each year suggest that perhaps over 200,000 
individuals die directly or indirectly as a results of DVT/PE in US. The clinical impact 
of DVT/PE is also highlighted by the fact that 10 % of hospital death can be attributed 
to PE, nevertheless it is the most common preventable cause of death. The morbidity 
and mortality of DVT/PE is not only confined to the first symptomatic acute event. A 
long-term complication of DVT is the post-thrombotic syndrome, consisting of chronic 
pain, swelling (or edema) and occasionally ulceration of the leg, which are observed in 
about 30 % of patients after 2 years. An immediate and adequate course of anticoagulant 
drugs is the mainstay therapy of DVT/PE in the acute phase as well as in post-acute 
phase for prolonged prevention of recurrent events. 
The most common risk factors are recent surgery or hospitalization. And 40 % of 
these patients did not receive heparin prophylaxis. The chance of developing DVT/PE 
during or after a surgical procedure varies with the nature of the procedure, including its 
duration, and with perioperative care. A comprehensive body of research has established 
that pharmacologic measures to prevent DVT/PE in appropriate surgical patients are 
both effective and associated with a low risk of postoperative bleeding complications. 
Therefore, the risk/benefit ratio favors the prophylactic approach to treatment. In 
addition, this approach has proven to be cost-effective in moderate- and high-risk 
general surgery patients. Other risk factors include advanced age, obesity, infection, 
immobilization, use of hormonal contraception, smoking and air travel are some of the 
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better-known causes.  
Major orthopaedic surgery, involving hip or knee replacement surgery or hip fracture 
surgery, is associated with a high risk of DVT/PE [32]. The risk results from stasis of 
venous blood flow as well as direct injury to the veins during surgery. Without 
prophylaxis, rates of DVT range from 40 % to 60 % when assessed by venography at 7 
to 14 days after major orthopaedic surgery [33]. Routine ventilation-perfusion scans in 
patients following hip or knee arthroplasty revealed pulmonary emboli in 3 % to 28 % 
of patients. Initial anticoagulation for DVT/PE prophylaxis and treatment is either 
unfractionated heparin by continuous intravenous infusion, low-molecular-weight 
heparin (LMWH) by subcutaneous injection (once or twice daily), or fondaparinux by 
once-daily injections followed by treatment with an oral anticoagulant. Major risks 
associated with heparin are bleeding complications and heparin-induced 
thrombocytopenia (HIT) which is lower with LMWHs and fondaparinux. Patients with 
a history of HIT should receive an alternative anticoagulant, such as argatroban, 
lepirudin, or danaparoid. Osteoporosis is another potential adverse effect when heparin 
is administered for longer than a month. Long-term treatment generally requires a 
transition from heparin or fondaparinux to a vitamin K antagonist (VKA), such as 
warfarin. VKAs have a delayed onset of anticoagulant effect; following initiation of 
VKA therapy, heparin can be discontinued once the INR has reached the therapeutic 
range (2.0 to 3.0). Treatment with warfarin for four weeks to twelve months has been 
shown to reduce the risk of DVT recurrence by 90 %. One exception to this general 
approach is the cancer patient with DVT, in whom long-term treatment with warfarin is 
less effective in preventing recurrence [34]. LMWH, shown in one study to be roughly 
twice as effective in preventing this outcome, should be considered in these patients. 
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Cardio embolic stroke prevention in atrial fibrillation 
  Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 
approximately 2.2 million Americans [35]. The prevalence of AF increases with age, 
with 70 % of case occurring in patients between the ages of 65 years and 85 years. AF is 
also more common in men than in women at all ages. The prevalence and incidence of 
AF are expected to increase in the coming decades because of the aging of the 
population; improved survival rates associated with coronary heart disease, heart failure 
and hypertension; and increased rate of performance of surgical procedures. It is 
projected that 7.5 million individuals will have AF in the US by the year 2020 [36]. The 
economic burden of AF is substantial because of high rates of hospitalization and other 
health resource utilization. Ischemic stroke is the most devastating complication of AF. 
Risk factors for stroke in patients with AF include recent congestive heart failure, 
hypertension, advanced age, diabetes and history of stroke or transient ischemic attack. 
Risk scoring systems, such as CHADS2, have been developed to predict an individual’s 
risk for developing AF and risk for stroke in AF patients. Oral VKAs like warfarin are 
extremely effective in reducing the risk of stroke among patients with AF. The early trial 
consistently demonstrated benefit with an overall 68 % risk reduction in stroke. Despite 
this dramatic efficacy, warfarin remains underused in clinical practice. Intracranial 
hemorrhage is the most feared complication of anticoagulant therapy. Mortality related 
to intacerebral hemorrhage approximates 50 % and is related to hematoma volume and 
hematoma expansion. Risk factors of intracranial hemorrhage include anticoagulation 
intensity, age, prior stroke, hypertension, concomitant antiplatelet therapy, and arterial 
vasculopathy. The paradox facing clinicians and patients is that many of the risk factors 
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for intracranial hemorrhage are also risk factors for ischemic stroke. When assessing 
risk versus benefit, current evidence from randomized controlled trail and observational 
studies weighs in favor of anticoagulant therapy. The rate of intracranial hemorrhage is 
approximately 0.5 - 0.6 %. The rate of major extracranial hemorrhage is 2 %. On the 
other hand, the rate of stroke among individuals with AF and multiple risk factors 
exceeds 10 %. However, there are important caveats to the published rates of major 
hemorrhage. Recent trials and most observational cohorts have largely reported the 
outcomes of prevalent users of warfarin. Because most major bleeding occurs early in 
the course of coagulation, enrollment of predominantly long-time users of warfarin will 
result in lower estimates of hemorrhage. This survival bias was illustrated by an 
inception cohort study of patients with AF aged 65 years and greater those were newly 
starting warfarin therapy. The rate of major hemorrhage in the first year was 7 % and 
discontinuation of warfarin was highest in the first 90 days. The cessation of warfarin 
was disproportionately high among patients at the highest risk of stroke.  
 
Coronary artery disease/ myocardial infarction 
Coronary artery disease (CAD) or atherosclerotic heart disease is the end result of the 
accumulation of atheromatous plaques. It is sometimes also called coronary heart 
disease (CHD), but although CAD is the most common cause of CHD, it is not the only 
cause. CAD is the leading cause of death worldwide [37]. While the symptoms and 
signs of coronary artery disease are noted in the advanced state of disease, most 
individuals with coronary artery disease show no evidence of disease for decades as the 
disease progresses before the first onset of symptoms, often a "sudden" heart attack, 
finally arises. Myocardial infarction (MI) or acute myocardial infarction (AMI), 
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commonly known as a heart attack, is the interruption of blood supply to part of the 
heart, causing some heart cells to die. This is most commonly due to occlusion of a 
coronary artery following the rupture of a vulnerable atherosclerotic plaque, which is an 
unstable collection of lipids (fatty acids) and white blood cells (especially macrophages) 
in the wall of an artery. The resulting ischemia and oxygen shortage, if left untreated for 
a sufficient period of time, can cause damage or infarction of heart muscle tissue. 
Myocardial infarction is a common presentation of ischemic heart disease. The WHO 
estimated that in 2002, 12.6 % of deaths worldwide were from ischemic heart disease. 
Ischemic heart disease is the leading cause of death in developed countries, but third to 
AIDS and lower respiratory infections in developing countries. In the United States, 
diseases of the heart are the leading cause of death, causing a higher mortality than 
cancer [37]. Coronary heart disease is responsible for 1 in 5 deaths in the U.S. This 
means that roughly every 65 seconds, an American dies of a coronary event. In India, 
cardiovascular disease (CVD) is the leading cause of death. The deaths due to CVD in 
India were 32 % of all deaths in 2007 and are expected to rise from 1.17 million in 1990 
and 1.59 million in 2000 to 2.03 million in 2010. 
The patient will receive a number of diagnostic tests, such as an electrocardiogram 
(ECG). On the basis of the ECG, a distinction is made between ST elevation MI 
(STEMI) or non-ST elevation MI (non-STEMI). Most cases of STEMI are treated with 
thrombolysis or if possible with percutaneous coronary intervention (PCI, angioplasty 
and stent insertion), provided the hospital has facilities for coronary angiography. 
NSTEMI is managed with medication, although PCI is often performed during hospital 
admission. In patients who have multiple blockages and who are relatively stable, or in 
a few extraordinary emergency cases, bypass surgery of the blocked coronary artery is 
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an option. 
The risk of a recurrent myocardial infarction decreases with strict blood pressure 
management and lifestyle changes, chiefly smoking cessation, regular exercise, a 
sensible diet for patients with heart disease, and limitation of alcohol intake. Patients are 
usually commenced on several long-term medications post-MI, with the aim of 
preventing secondary cardiovascular events such as further myocardial infarctions, 
congestive heart failure or cerebrovascular accident (CVA). Unless contraindicated, 
such medications may include antiplatelet drug, beta blocker, ACE inhibitor, statins and 
omega-3 fatty acids. Antiplatelet drug therapy, such as aspirin and/or clopidogrel, 
should be continued to reduce the risk of plaque rupture and recurrent myocardial 
infarction. Aspirin is first-line, owing to its low cost and comparable efficacy, with 
clopidogrel reserved for patients intolerant of aspirin. The combination of clopidogrel 
and aspirin may further reduce risk of cardiovascular events, however the risk of 
hemorrhage is increased [38]. 
 
Sepsis 
Sepsis is a serious medical condition that is characterized by a whole-body 
inflammatory state which is called a systemic inflammatory response syndrome (SIRS) 
and the presence of a known or suspected infection. The clinical syndrome of sepsis is 
characterized by the disruption in homeostasis through uncontrolled inflammation, 
which response to microbes in the blood, urine, lungs, skin, or other tissues, coagulation 
and fibrinolysis [39-41]. In the US, sepsis causes an estimated 240,000 deaths/year and 
has related costs of US $20 billion/year. It has an annual increase of 1.5 – 8 %/year, 
probably as the result of increased number of patients with advanced age, compromised 
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immune status, increased use of invasive procedures and an increased prevalence of 
antibiotic-resistant organisms [34]. Despite enormous progress in intensive care therapy, 
the mortality rate of 30 – 50 % among septic patients has remained almost unchanged 
over the last 30 years. In Europe, the reported incidence of severe sepsis varies from 54 
cases/100,000 peoples in Netherlands to 66 cases/100,000 people in the UK. The 
number of patients with severe sepsis treated in the UK has increased from 46/100,000 
in 1996 to 66/100,000 in 2003. The mortality from severe sepsis in the EU may be 
30/100,000/year corresponding to 110,600 deaths/year. 
The therapy of sepsis rests on antibiotics, surgical drainage of infected fluid 
collections, fluid replacement and appropriate support for organ dysfunction. This may 
include hemodialysis in kidney failure, mechanical ventilation in pulmonary 
dysfunction, transfusion of blood products, and drug and fluid therapy for circulatory 
failure. Ensuring adequate nutrition, preferably by enteral feeding, but if necessary by 
parenteral nutrition, is important during prolonged illness. A problem in the adequate 
management of septic patients has been the delay in administering therapy after sepsis 
has been recognized. Published studies have demonstrated that for every hour delay in 
the administration of appropriate antibiotic therapy there is an associated 7 % rise in 
mortality. Most therapies aimed at the inflammation process itself have failed to 
improve outcome, however drotrecogin alfa (activated protein C) has been shown to 
decrease mortality from about 31 % to about 25 % in severe sepsis [42]. To qualify for 
drotrecogin alfa, a patient must have severe sepsis or septic shock with an APACHE II 
score of 25 or greater and a low risk of bleeding. 
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CHAPTER II: Discovery of ER-410660 and its prodrug form E5539 
Compound optimization and finding of ER-410660 as a selective TF/VIIa inhibitor 
Our drug discovery project was initiated to find a potent and selective TF/VIIa 
complex inhibitor. In September 1999, a high-throughput screening (HTS) system was 
established for finding inhibitors of the TF/VIIa complex formation or compounds 
blocking the FVIIa active-site. The HTS campaign was completed in December 1999, 
and resulted in the discovery of one Eisai original “trigger” compound. Synthetic 
optimization was next performed, but the hoped for improvement in TF/VIIa inhibitory 
potency could not be achieved. Therefore, Roche patent compound was selected instead 
as the starting point for product creation. As a result, we found good “seed” compounds 
which contains both an amidine and a carboxylic acid moiety. Choosing this approach 
left three issues to be solved. These were 1) oral bioavailability, 2) compound potency, 
and 3) patentability. The oral bioavailability of “seed” compound was very low because 
of poor membrane permeability. One of the reasons for this may be the strong basicity 
of the amidine group. However an amidine or equivalent moiety was indispensable for 
TF/VIIa inhibition. In fact, we did try to find an alternative to this amidine, but it was 
concluded that, at least for this template, it was impossible to replace the amidine 
effectively with another less basic moiety. Hence, at this point it was decided to opt for 
a prodrug strategy for solving issue 1). 
Conversion of the carboxylic acid was effective for solving issues 2) and 3). 
Conversion into hydrazide derivatives maintains activity. However, active carboxylic 
acid derivatives, including these hydrazide analogues, were easily hydrolyzed back to 
the carboxylic acid in plasma. Next we tried converting the hydrazide linker moiety into 
a cyclic linker which was assumed to be harder to metabolism. Triazolone analogues 
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(compound 1) were prepared as these maintain the essential structural features of active 
amide and hydrazide analogues, a carbonyl group, an acidic proton and the possibility 
of aryl group attachment, while being resistant to hydrolysis (Fig. 2). Typical synthesis 
route of triazolone derivatives were shown in Fig.3.  
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Fig.2. Remarkable inhibitory activity of triazolone derivative on TF/VIIa activity 
and selectivity against other serine proteases. 1) The 1.1x PT is defined as the 
concentration of compound needed to prolong the clotting formation time by 1.1-fold in 
the prothrombin time (PT) assay. 2) The 2x APTT is defined as the concentration of 
compound needed to prolong the clotting formation time by 2-fold in the activated 
partial prothrombin time (aPTT) assay. 
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Fig.3. Typical synthetic route of triazolone derivatives as potent and selective 
TF/VIIa inhibitor. 
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Optimization of the B- and D-rings of triazolone analogues (compound 1) were 
started to find clinical developable TF/FVIIa inhibitors. Table 1 shows the SAR of 
A-ring optimization. When compared with lead compound 1 having an unsubstituted 
phenyl A-ring compounds having substituted phenyl or heteroaryl on the triazolone ring 
showed significant improvements in their selective inhibitory effects on extrinsic blood 
coagulation as indicated by PT assay results. Regarding substitution on the ring, 
ortho-substitution is well tolerated. Especially, a carboxy group shows potent inhibitory 
effects on the extrinsic pathway. The compounds 20, 21 and 22 having a carboxylic acid 
on a 5-membered heteroaryl display good selectivity against FXIa in comparison with 
benzoic acid 11. 
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Table 1: SAR of A-ring of triazolone derivatives 
 
*All compounds are supplied as chial. 1) The concentration to prolong the PT by 
1.1-fold. 2) The concentration doubling aPTT. 
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Since compounds 19, 20 and 21 had improved the potency and selectivity of the 
inhibitory effects on extrinsic blood coagulation, 2-carboxythiophene, 
5-carboxythiazole and pyrimidine ring were selected as A-ring candidates for further 
optimization focusing on their combination with the B-ring (Table 2, 3 and 4). As for 
the SAR of the B-ring, a wide range of substituents on the phenyl is well tolerated (e.g., 
halogen, alkyl, alkene, alkyne, alkoxy, hydroxyalkyl and oxygen containing fused ring 
etc.); also, the phenyl can be replaced by pyridyl without adversely affecting activity.  
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Table 2: SAR of thiophene containing triazolone derivatives 
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Table 3: SAR of thiazole containing triazolone derivatives 
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Table 4: SAR of pyrimidine containing triazolone derivatives 
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It should be noted that our drug target is in plasma, so during optimization, careful 
attention to plasma protein binding (PB) need to be paied. PB directly affects the 
activity of these compounds in plasma. To enhance their potency, consideration of not 
only VIIa inhibition but also PB (or hydrophilicity) was essential. In general, more polar 
compounds tend to have lower PB, and this is reflected in the fact that our compounds 
are very hydrophilic. 
In vivo efficacy and bleeding time prolongation of a number of these compounds was 
evaluated in a rat model (detailed data not shown). The results clearly suggest that 
TF/VIIa plays a significant role in clotting formation and that it is a suitable target for 
development of a novel anticoagulant with low bleeding risk. As far as pharmacological 
potency is concerned, this series of triazolone derivatives has reached the level 
necessary for a promising candidate novel anticoagulant. Especially, compounds 29, 31 
and 36 (ER-410660) were nominated for further prodrugging research to improve oral 
availability. However, it was difficult to predict the human pharmacokinetics (PK) 
profile of these inhibitors due to the poor reliability of prediction from animal scale-up. 
In addition, a human PK profile, especially half-life in plasma (t1/2), is important in the 
selection of the most suitable compound for its prodrugging research. Therefore, a 
human micro dosing study of compounds 29, 31 and 36 was conducted in Netherland. 
Summarized human PK results are shown in Fig. 4. 
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Fig.4. Results of human microdosing studies of compounds 29, 31 and 36 
(ER-410660). 
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Study design
 Single dose, open-label, 3 period fixed sequence crossover
 5 subjects, healthy male adult volunteers, to receive all 3
compounds as a microdose with 1 week washout between
treatments
 Dose: 100 μg and 100 nCi 1), given iv over 15 min infusion
 PK sampling for 48 h (plasma, urine and feces)
1) Labeled material for the study was prepared by Selcia Co. Ltd.
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The t1/2 of each of the three compounds is about 9 hr and the human 
pharmacokinetics (PK) of the three compounds is very similar. They were not 
metabolized and were mainly excreted to urine. Thus all three compounds satisfy our 
PK criteria, and from this point of view anyone of them is suitable for further 
development. To address issue of oral availability, prodrug formation was attempted for 
compounds 29, 31 and 36 (ER-410660). From this initial examination, I concluded that 
ER-410660 had the highest potential for improving bioavailability by a prodrug 
strategy.  
To understand the reason for bringing high potency against TF/VIIa complex and 
selectivity among various coagulation factors by ER-410660, the X-ray crystal structure 
of compound with FVIIa enzyme was analyzed. Fig. 5 shows the feature of specific 
interaction of ER-410660 to FVIIa enzyme. 
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Fig. 5. X-ray co-crystal structure of ER-410660 with human FVIIa. 
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Discovery of E5539 as a prodrug form of ER-410660 
As mentioned in CHAPTER II, three promising compounds were in hand, the potent 
and highly selective TF/VIIa inhibitors, such as compounds 29, 31 and 36 (ER-410660). 
Nevertheless, our active compounds had some issues that needed to be solved. These 
were 1) difficulty of human PK prediction 2) low bioavailability. It was needed to select 
one active compound for further prodrug investigation based on data on human PK, and 
the degree of BA improvement obtained in preliminary explorations. In order to solve 
issue 1), a human micro dosing study was conducted and human PK profiles were 
cleared. To address issue 2), prodrug formation was attempted for these compounds. 
One of the major reasons for the poor membrane permeability of ER-410660 may be 
their strong basicity, which is due to their amidine moiety. However, our initial studies 
showed that prodrug formation is necessary not only to mask the amidine moiety but 
also the triazolone moiety of compound. That is, it is necessary to mask both the 
amidine moiety with benzoate or carbamate and the triazolone as pivaloyl oxymethyl 
derivatives or esters (Fig. 6). 
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Fig. 6. Design of prodrug form of ER-410660 to improve its oral availability. 
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This double prodrug formation, or triple prodrug formation with the hydroxyl group 
also masked, was effective at improving the oral bioavailability of ER-410660. More 
than one thousand prodrugs of ER-410660 were synthesized and confirmed their oral 
bioavailability. As a result, three prodrugs were found as attractive compounds for 
further development. Among these prodrugs, E5539 showed the highest BA in all 
preclinical animals. The PK profile of E5539 in mouse, rat, and rhesus monkey are 
summarized in Table 5. Improvement of oral BA by prodrug formation was obvioused 
in mice, rats and rhesus monkeys at doses of 1-5 mg/kg. To evaluate the intrinsic 
absorption, a solution containing 2-4 % DMSO and 10 % Tween 20 was used as a 
dosing vehicle to solve E5539 completely. The BA was calculated by dividing AUC 
value of ER-410660 after oral dosing of E5539 by that after intravenous (iv) dosing of 
ER-410660, giving the results 47.2, 3.9 and 17.0 % in mice, rats and rhesus monkeys, 
respectively. Although the BA in rat was relatively low compared to those in the other 
two species, a significant improvement due to prodrug formation was observed by 
E5539 in all species studied. 
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Table 5: PK parameters of ER-410060 after oral administration of E5539 (A) and 
comparison of BA values in mice, rats and rhesus monkeys (B) 
 
(A) 
 
 
(B) 
 
Species 
Bioavailability as ER-410660 (%) 
Fold increase 
ER-410660 E5539 
Mouse 2.9 47.2 16 
Rat 0.8 3.9 4.9 
Monkey 2.9 17.0 5.7 
 
E5539 dissolved with 2-4 % DMSO and 10 % Tween 20 was administered to mice, rats 
and monkeys at the doses of 1-5 mg/kg. 
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CHAPTER III: In vitro pharmacological assessment of ER-410660 
Objective 
The in vitro enzyme inhibitory profile and anticoagulation selectivity of the TF/VIIa 
complex inhibitor, ER-410660 were assessed using enzyme inhibitory assay on several 
coagulation factors and plasma clotting assays. 
 
Material and Methods 
Reagents 
ER-410660 was synthesized by Tsukuba Research Laboratories, Eisai Co., Ltd. 
(Ibaraki, Japan). L-α-cephalin, human thrombin, and pancreatic trypsin were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human TF was purchased 
from Calbiochem (La Jolla, CA, USA), and human factors VIIa, IXa, Xa, XIa, and XIIa 
were purchased from Enzyme Research Laboratories (South Bend, IN, USA). 
Chromozym TH; Spectrozyme® FVIIa; and Pefachrome® FIXa, FXIIa, and TRY were 
obtained from Roche (Indianapolis, IN, USA), American Diagnostica (Stamford, CT, 
USA), and Pentapharm (Basel, Switzerland), respectively. S-2765 was purchased from 
Daiichi Pure Chemicals (Tokyo, Japan), and 0.02 mol/L CaCl2 was obtained from 
Sysmex Co. (Hyogo, Japan). Thromborel S, activated cephaloplastin reagent, and 
thromboplastin C+ were obtained from Dade Behring Marburg GmbH (Marburg, 
Germany).  
 
Pooled plasma preparation 
Rhesus monkeys (n = 27) and Crl:CD (SD) rats (n = 11) were anesthetized by 
intramuscular administration of a combination of ketamine (5 mg/kg) and xylazine (2 
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mg/kg) or pentobarbital (50 mg/kg), respectively. Blood, 3 mL from a saphenous vein 
(rhesus monkey) and 10 mL from the abdominal aorta (rat), was drawn using syringes 
containing 3.8% sodium citrate, and centrifuged at 1,500 × g (Kubota 8850; Kubota, 
Tokyo, Japan) for 10 min at room temperature. The resultant plasma was pooled, 
according to species, and stored at –80°C. Human pooled plasma was purchased from 
George King Bio-Medical (Overland Park, Kansas, USA). 
 
Enzyme inhibitory assays 
Enzyme solutions are shown in Table 6 and were prepared on the day of use. Enzyme 
assays were performed by incubating a 110 mL sample of each enzyme solution with 15 
mL of the various concentrations of ER-410660 (100 mmol/L dissolved in dimethyl 
sulfoxide (DMSO) and diluted with buffer 1 (100 mmol/L Tris-HCl, 150 mmol/L NaCl, 
and 1.0 mg/mL BSA; pH 7.4)). Enzyme-specific substrate solution (25 µL of each; final 
volume = 150 mL) was added to initiate the reaction. The enzymatically released 
p-nitroanilide was measured by its absorbance at 405 nm. Changes in absorbance were 
monitored using a microplate reader (SpectraMax 190, Molecular Devices, Sunnyvale, 
CA, USA). The activities of thrombin, factors IXa, factor Xa, factor XIa, factor XIIa, 
and trypsin were monitored for 10 min at room temperature, and the activity of TF/VIIa 
was monitored for 40 min, also at room temperature.  
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Table 6: Enzyme solutions and substrates 
Enzyme 
Solution 
Buffer Buffer Solution Final Enzyme 
Concentration(s) 
Substrate 
Thrombin  Buffer 1 
(pH 7.4) 
100 mmol/L Tris-HCl  
150 mmol/L NaCl 
1.0 mg/mL bovine 
serum albumin 
   (BSA)  
0.10 U/mL  Choromozym 
TH 
TF/VIIa 
complex 
Buffer 2  
(pH 7.4) 
Buffer 1  
15 mmol/L CaCl2  
30 mg/mL L-α-cephalin 
0.39 mg/mL TF 
and 0.30 mg/mL 
VIIa 
Spectrozyme 
FVIIa 
Factor IXa Buffer 3  
(pH 7.4) 
Buffer 1 
40% ethylene glycol 
7.0 mg/mL Pefachrome 
FIXa 
Factor Xa Buffer 1 
(pH 7.4) 
100 mmολ/L Tris-HCl  
150 mmol/L NaCl 
1.0 mg/mL BSA 
5.0 mU/mL S-2765 
Factor XIa Buffer 1  
(pH 7.4) 
100 mmol/L Tris-HCl  
150 mmol/L NaCl 
1.0 mg/mL BSA 
1.5 mg/mL Pefachrome 
FXIa 
Factor XIIa Buffer 1  
(pH 7.4) 
100 mmol/L Tris-HCl  
150 mmol/L NaCl 
1.0 mg/mL BSA 
1.0 mg/mL Pefachrome 
FXIIa 
Trypsin Buffer 1  
(pH 7.4) 
100 mmol/L Tris-HCl  
150 mmol/L NaCl 
1.0 mg/mL BSA 
1.0 U/mL Pefachrome 
TRY 
*Chromozym TH; Spectrozyme FVIIa; S-2765; and Pefachrome FIXa, FXIIa, and TRY 
were each dissolved in purified water to make 1.0 mmol/L solutions. Pefachrome FXIa 
was dissolved in purified water to make 2.0 mmol/L solutions. 
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Plasma Clotting Assay 
ER-410660 was dissolved in DMSO to yield a 100 mmol/L concentration, and 
serially diluted with vehicle (100 mmol/L Tris-HCl and 1.0 mg/mL BSA; pH 7.4). All 
solutions were prepared on the day of use. Plasma (90 mL) was incubated with the drug 
solution or vehicle (10 mL) for 2 min at 37°C before clot formation commenced. In the 
prothrombin time (PT) test, clotting was initiated by adding thromborel S solution (200 
mL) to each incubated sample. In the activated partial thromboplastin time (aPTT) test, 
activated cephaloplastin reagent (100 mL) was incubated with each sample for 1 min at 
37°C. CaCl2 solution (100 mL; 0.02 mol/L) was then added to initiate clot formation. 
Coagulation time was determined using a coagulometer (KC10A, Amelung GmbH, 
Lemgo, Germany), and the anticoagulant effect was determined using the following 
formula: 
Anticoagulant effect (percentage of control) = A/B × 100, where A = coagulation time 
of samples with drug and B = coagulation time of control. 
The concentration that increased the time taken to reach coagulation by 150% in the PT 
test and 200% in the aPTT test were defined as PT × 1.5 and aPTT × 2.0, respectively.  
 
Statistical Analyses 
All statistical analyses were conducted using the SAS 8.1 or 8.2 software packages 
(SAS Institute Japan, Tokyo, Japan), and all results are expressed as the means ± 
standard error of the mean (SEM). For the in vitro enzyme assays, the inhibitory 
constant (Ki) was calculated according to the Cheng–Prusoff equation (Ki = IC50/1 + 
[S]/Km), where [S] is the substrate concentration and Km is the Michaelis–Menten 
constant. The mean IC50 value and the 95% confidence intervals (CI) were determined 
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based on the IC50 values generated from separate sigmoid curves representing the 
activity of each enzyme versus the ER-410660 concentration from 3 individual 
experiments. For the in vitro coagulation assays, the mean values and the 95% CIs were 
determined from the PT × 1.5 and aPTT × 2.0 values generated from separate regression 
lines, representing each anticoagulant activity value versus the ER-410660 
concentration of 3 individual experiments. 
 
Results 
Inhibitory potency of ER-410660 on TF/VIIa complex and selectivity 
against other coagulation factors  
The Ki values and 95% CIs of ER-410660 for each enzyme are summarized in Table 
7. ER-410660 inhibited TF/VIIa activity (Ki value of 0.0049 mmol/L), but only slightly 
inhibited factors IXa, factor Xa, and factor XIIa, even at a higher concentration (100 
mmol/L) than that used to inhibit TF/VIIa activity. The Ki values for thrombin, factor 
XIa, and trypsin were 1.1, 0.67 and 1.9 mmol/L, respectively, and these values were 
224-fold, 137-fold, and 388-fold higher than those of TF/VIIa, respectively. 
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Table 7: Human protease inhibitory profile of ER-410660 
 
Data shown are the means of Ki values and 95% confidential intervals (CI) determined 
from the results of 3 separate experiments; each performed in triplicate. 
  
Thrombin TF/VIIa IXa Xa XIa XIIa Trypsin
ER-410660 1.1 0.0049 >100 >100 0.67 >100 1.9
(0.87 - 1.6) (0.0028 - 0.0083) (0.36 - 1.3) (1.1 - 3.2)
Ki (mmol/L)
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Anticoagulation potency of ER-410660 and its pathway selectivity 
The relationships between the ER-410660 concentration and the anticoagulant effects 
on PT and aPTT in human, rhesus monkey, and rat plasma are shown in Fig. 4A-B. 
ER-410660 increased the PT in human, rhesus monkey, and rat plasma in a 
concentration-dependent manner. In the PT assay, ER-410660 showed almost equal 
anticoagulant activity in human and rhesus monkey plasma, but was approximately 10 
times less potent against rat plasma. The PT × 1.5 values were 2.0, 1.7, and 19 mmol/L 
in human, rhesus monkey, and rat plasma, respectively. A much higher concentration of 
ER-410660 was necessary to double the aPTT in human, rhesus monkey, and rat plasma, 
and the ratio of aPTT × 2.0 to PT × 1.5 for ER-410660 in human, rhesus monkey, and 
rat plasma was 25, 18, and 4.6, respectively (Table 8). 
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(A) 
 
(B) 
 
Fig. 4. Anticoagulation potency of ER-410660 in human, rhesus monkey, and rat 
plasma. The anticoagulation effect at each ER-410660 concentration is shown as a 
percentage of the control. (A) Prolongation of PT; (B) Prolongation of aPTT. Each data 
point represents the mean ± SEM from 3 independent experiments, performed in 
triplicate. 
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Table 8: Concentration required to prolong coagulation time by 150% in the PT 
assay (PT × 1.5) and by 200% in the aPTT assay (aPTT × 2.0) in human, rhesus 
monkey and rat plasma. 
  
The mean values and the 95% CIs were determined from the PT × 1.5 and aPTT × 2.0 
values generated from separate regression lines representing each anticoagulation 
activity value versus compound concentrations from 3 individual experiments. 
  
Human Rhesus monkey Rat
PTx1.5 2.0
(1.1-3.4)
1.7
(1.2-2.4)
19
(18-19)
aPTTx2.0 50
(42-59)
30
(27-34)
88
(67-110)
Selectivity 25 18 4.6
ER-410660 (mmol/L)
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Discussion 
In the present study, ER-410660 was proved as a potent enzyme inhibitor of the 
TF/VIIa complex, with a Ki value of 0.0049 mmol/L. Although ER-410660 had a slight 
inhibitory effect on thrombin and XIa, it was more than 100 times more selective than 
other coagulation enzymes. In preliminary experiments, ER-410660 also did not show 
inhibitory activity against tissue plasminogen activator, plasmin, and activated protein C 
at concentrations of ≤10 μmol/L. ER-410660 selectively prolonged PT, but had little 
effect on aPTT in human, rhesus monkey, and rat plasma. Theoretically, a TF/VIIa 
inhibitor should not affect the aPTT assay. The prolonged aPTT, caused by the addition 
of a high concentration of ER-410660, may be due to its ability to weakly inhibit 
thrombin and XIa activity. To achieve PTx1.5, ER-410660 needed around 10 times 
higher concentrations in rat plasma than in human plasma. On the other hand, there are 
no siginificant species differences between rhesus monkey and human in terms of 
anticoagulation potency in plasma. 
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CHAPTER IV: In vivo pharmacological activity of ER-410660 and E5539 
Objective 
In vivo effects of ER-410660 and E5539 were determined using a TF-induced, 
thrombin generation rhesus monkey model, a stasis-induced venous thrombosis rat 
model, a photochemically-induced arterial thrombosis rat model, and a rat tail-cut 
bleeding model. 
 
Material and Methods 
Reagents 
ER-410660, E5539, and active comparators, such as dabigatran and rivaroxaban, 
were synthesized by Tsukuba Research Laboratories, Eisai Co., Ltd. (Ibaraki, Japan). 
Rose bengal was purchased from Sigma-Aldrich (St. Louis, MO, USA). Thromboplastin 
C+, and Enzygnost thrombin-antithrombin (TAT) were obtained from Dade Behring 
Marburg GmbH (Marburg, Germany).  
 
TF-induced, thrombin generation in a rhesus monkey model 
Before the beginning of study, Laboratory Animal Care and Use Committee at Eisai 
Co., Ltd. had approved all of studies plan. These studies were performed in compliance 
with Laboratory Animal Policy at Eisai. ER-410660 was dissolved in vehicle solution 
(5% glucose containing 1% DMSO and 0.05 mol/L HCl) to yield 0.06, 0.2, and 0.6 
mg/mL solutions. Thromboplastin C+ was dissolved in saline to yield a 100 mU/mL TF 
solution. All dosing formulations were prepared on the day of use, unless otherwise 
indicated. The experiment consisted of 4 treatments: vehicle (control), 0.03 mg/kg, 0.1 
mg/kg, and 0.3 mg/kg ER-410660. One group of 8 male rhesus monkeys (4–
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5-years-old) was used in each of the 4-period crossover experiments. The 4 treatments 
were administered separately, with at least 7 days washout between compound and 
vehicle dosing.  
The monkeys were anesthetized by intramuscular administration of ketamine (5 
mg/kg) and xylazine (2 mg/kg). ER-410660 or vehicle (0.5 mL/kg) was administered 
intravenously, via the left femoral vein, 2 minutes prior to the TF injection (50 mU/kg in 
a volume of 0.5 mL/kg) in the right femoral vein. Blood (0.4 mL) was drawn from a 
cephalic vein 5 minutes later using a syringe with an added 40 mL of 3.8% sodium 
citrate and centrifuged at 3,000 × g for 5 min at room temperature. De novo, TF-induced 
thrombin generation was determined by measuring the plasma TAT complex levels 
using an enzyme-linked immunosorbent assay kit (Enzygnost TAT). The absorbance 
was measured at 492 nm using a microplate spectrophotometer.  
 
Stasis-induced, venous thrombosis rat model 
Thromboplastin C+ was dissolved in saline to yield a 4 mU/mL TF solution on the 
day of use. In the first experiment, ER-410660 was dissolved in the vehicle solution 
(5% glucose containing 1% DMSO and 0.05 mol/L HCl) to yield 0.1, 0.3, and 1.0 
mg/mL solutions. SD rats (males, 10-weeks-old) were randomly allocated to 4 groups (5 
animals/group): vehicle (control), 0.1 mg/kg, 0.3 mg/kg, and 1.0 mg/kg ER-410660.  
For the second set of experiments, 1, 3, and 10 mg/mL dabigatran solutions and 20, 60, 
and 200 mg/mL rivaroxaban solutions were prepared, using the same vehicle solution as 
was used for ER-410660. SD rats were randomly allocated to 7 groups (5 
animals/group): vehicle (control); 1 mg/kg, 3 mg/kg, and 10 mg/kg dabigatran; and 20 
mg/kg, 60 mg/kg, and 200 mg/kg rivaroxaban. 
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Rats were weighed and anesthetized by intraperitoneal injection of pentobarbital 
sodium (55 mg/kg). After surgically opening the abdomen, the branches of the inferior 
vena cava were ligated. The vehicle or compound solutions were injected via the 
femoral vein in a volume of 1 mL/kg, followed by 4 mU/kg thromboplastin C+, 30 s 
later. Venous thrombosis was then induced by tight ligation of the inferior vena cava just 
below the left renal venous branch, 30 s after the injections. Ten min later, the vena cava 
was clamped, 1.5 cm from the left renal venous branch, and the vascular segment was 
longitudinally opened to allow the removal of the thrombus. The thrombus was gently 
removed and placed on filter paper for 1 min to remove any blood from the surface. It 
was then transferred into a tube, which was tightly sealed until an accurate weighing 
could be performed.  
 
Photochemically-induced, arterial thrombosis rat model 
As an initial experiment, ER-410660 was dissolved in vehicle (5% glucose) at a 
concentration of 3 mg/mL, and diluted with vehicle to yield 1 and 0.3 mg/mL solutions. 
SD rats (males, 10-weeks-old) were randomly allocated to 4 groups (8 animals/group): 
vehicle (control), 0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg ER-410660.  
For the second set of experiments, 0.03, 0.1, and 0.3 mg/mL dabigatran solutions and 
0.1, 0.3, and 1.0 mg/L rivaroxaban solutions, in 5% glucose, were prepared. SD rats 
were randomly allocated to 7 groups (5 animals/group): vehicle (control); 0.03 mg/kg, 
0.1 mg/kg, and 0.3 mg/kg dabigatran; and 0.1 mg/kg, 0.3mg/kg, and 1.0 mg/kg 
rivaroxaban. 
The rats were weighed and anesthetized by intraperitoneal injection of pentobarbital 
sodium (50 mg/kg). The left femoral vein was exposed to inject compound, vehicle, or 
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rose bengal solutions. The right femoral artery was exposed and the connective tissue 
around the artery was carefully separated. A pulsed Doppler flow probe (HHD-20, 
Crystal Biotech, Northborough, MA, USA) was attached to the femoral artery to 
measure blood flow. Transillumination of green light (540 nm wavelength, 500,000 
Lux) was achieved with an irradiation apparatus (L4887, Hamamatsu Photonics, 
Hamamatsu, Japan). The irradiation was provided through an optical fiber (A5355, 
Hamamatsu Photonics) positioned 5–10 mm above a femoral artery segment, proximal 
to the flow probe. Blood flow was measured with the pulsed Doppler flow probe 
connected to a pulsed Doppler module (PD-1, Valpey-Fisher). Blood flow was 
continuously recorded on a thermal array recorder (WS-682G, Nihon Kohden, Tokyo, 
Japan). After establishing the baseline blood flow, irradiation to the femoral artery was 
initiated. Four min after starting the irradiation, ER-410660, at doses of 0.3, 1, and 3 
mg/kg, or vehicle was injected intravenously into the left femoral vein at a volume of 1 
mL/kg, followed by 10 mg/kg of rose bengal 1 min later. 
The time required to occlude the femoral artery after the injection of rose bengal was 
measured. Cessation of femoral blood flow was judged by the monitor sounds of the 
Doppler meter. The artery was considered occluded when the blood flow was 
completely stopped for > 2 min. Irradiation was continued until either the artery was 
completely occluded or up to a maximal observation time of 30 min. The time to 
occlusion (TTO) was determined by measuring the time from the injection of rose 
bengal to the complete cessation of blood flow, using a chart recorder with a vernier 
caliper set to ‘mm’. The chart speed of the thermal recorder was 10 mm/min, and the 
TTO was presented as ‘min’. 
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Rat ex vivo coagulation assay after intravenous administration 
ER-410660 was dissolved in 5% glucose at a concentration of 1 mg/mL. SD rats 
(males, 10-weeks-old, n = 3) were weighed and anesthetized by intraperitoneal 
injection of pentobarbital sodium (50 mg/kg). The left femoral vein was 
exposed to inject the compound. Blood (0.45 mL) was drawn from a jugular vein 
before, and 1, 5, and 15 min after drug administration, using a syringe containing 0.05 
mL of 3.8% sodium citrate. Blood was centrifuged at 1,500 × g for 5 min at room 
temperature, and prepared plasma was used for the coagulation time (PT and aPTT) 
measurements.  
 
Rat tail-cut bleeding model 
ER-410660 was dissolved in 5% glucose at a concentration of 7.5 mg/mL, and further 
diluted with vehicle to yield 5.0 and 2.5 mg/mL solutions. SD rats (males, 
10-weeks-old) were randomly allocated to 4 groups (8 animals/group): vehicle (control), 
2.5 mg/kg, 5.0 mg/kg, and 7.5 mg/kg ER-410660.  
For the second set of experiments, 0.03, 0.1, and 0.3 mg/mL of dabigatran and 0.02, 
0.06, 0.2, and 0.6 mg/mL of rivaroxaban solutions, in 5% glucose, were prepared. SD 
rats were randomly allocated to 8 groups (6 animals/group): vehicle (control); 0.03 
mg/kg, 0.1 mg/kg, and 0.3 mg/kg dabigatran; and 0.02 mg/kg, 0.06 mg/kg, 0.2 mg/kg, 
and 0.6 mg/kg rivaroxaban.  
Rats were weighed and then anesthetized by intraperitoneal injection of pentobarbital 
sodium (50 mg/kg). The vehicle or compound solutions were injected into the femoral 
vein at a volume of 1 mL/kg. After 1 min, the tail of the rat was transected 1 mm from 
the tip and immersed into 37°C saline. Bleeding was observed for 30 min. Complete 
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hemostasis was defined as the time point at which the bleeding had completely stopped 
for 5 min. In these cases, the experiment was terminated before the 30 min observation 
period.  
 
Pharmacological evaluation of prodrug E5539 in a TF-induced, 
thrombin generation rhesus monkey model 
E5539 was dissolved in vehicle (distilled water containing 10% Tween 20) at a 
concentration of 15 mg/mL and further diluted with vehicle to yield 5 mg/mL and 1.5 
mg/mL solutions. The dosing formulations were prepared on the first day of each 
experimental period. Thromboplastin C+ was dissolved in saline to yield a 100 mU/mL 
TF solution on the day of use. One group of 11 male rhesus monkeys was used in each 
of the 4-period crossover experiments. The 4 treatments were administered separately, 
with at least a 7-day washout period between compound and vehicle dosing.  
E5539 at doses of 3, 10 and 30 mg/kg, or vehicle, was orally administered in a 2 
mL/kg volume to the male rhesus monkeys. Blood (0.9 mL) was drawn from a brachial 
vein 3 h after the drug administration using a syringe containing 0.1 mL of 3.8% sodium 
citrate. TF solution (50 mU/kg) was then administered in a 0.5 mL/kg volume, via the 
right femoral vein, and blood (0.45 mL) was drawn from a brachial vein 5 min later, 
using a syringe containing 0.05 mL of 3.8% sodium citrate. The blood was centrifuged 
at 1,500 × g for 5 min at room temperature, and the prepared plasma was stored at –
80°C before coagulation time or TAT complex measurements. De novo, TF-induced 
thrombin generation was determined by measuring the plasma TAT levels using an 
Enzygnost TAT assay.  
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Statistical Analyses 
All statistical analyses were conducted using the SAS 8.1 or 8.2 software packages 
(SAS Institute Japan, Tokyo, Japan), and all results are expressed as the means ± 
standard error of the mean (SEM). For the in vivo models, ED50 values (the dose 
causing a 50% reduction relative to controls), TTO2 values (the dose required to double 
the TTO of the control group), and BT2 values (the dose required to double the total 
bleeding time of the control group) were calculated using linear regression with 95% 
CIs. Coagulation time experiments were performed in duplicate, and TAT levels were 
evaluated using one-way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparison test. A probability (p) value of < 0.05 (two-sided) was considered 
statistically significant. 
 
Results 
Inhibitory effect of ER-410660 on TF-induced thrombin generation in 
the rhesus monkey 
ER-410660 decreased de novo thrombin generation and reduced the size of the 
thrombi in a dose-dependent manner. De novo thrombin generation was induced by 
injection of the thromboplastin reagent in a rhesus monkey model and measured using 
plasma TAT levels. The plasma TAT level in the control group was 314 ± 37 ng/mL, and 
intravenous administration of ER-410660 decreased this level, with an ED50 value of 
0.040 mg/kg (95% CI, 0.025–0.055) (Fig. 5).  
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Fig. 5. Effects of ER-410660 on tissue factor (TF)-induced, thrombin-antithrombin 
(TAT) complex formation in rhesus monkey. Results are expressed as the mean ± 
SEM; n = 8 animals per group. 
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Effect of ER-410660 on venous thrombus formation in rats 
In the rat model, ER-410660 reduced venous thrombus weight, with an ED50 value of 
0.18 mg/kg (95% CI, 0.11–0.25) (Fig. 6A) in a stasis-induced venous thrombosis rat 
model, where the mean wet weight of the thrombi in the control group was 70.1 ± 4.6 
mg. An anti-venous thrombotic effect for dabigatran and rivaroxaban was also 
confirmed in the rat model, with ED50 values of 0.0033 (95% CI, 0.0028–0.0039) and 
0.074 mg/kg (95% CI, 0.056–0.097), respectively (Fig. 6B). 
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(A) 
 
(B) 
 
Fig. 6. Effect of ER-410660, dabigatran and rivaroxaban on venous thrombus 
weights in rat abdominal veins. (A) ER-410660 and (B) dabigatran and rivaroxaban. 
Results are expressed as the mean ± SEM; n = 5 animals/group. 
0
10
20
30
40
50
60
70
80
- 0.1 0.3 1
T
hr
om
bu
s 
W
ei
gh
t (
m
g)
Control ER-410660 (mg/kg)
 
0
10
20
30
40
50
60
70
80
90
100
Control 1 3 10 20 60 200
Th
ro
m
bu
s 
W
ei
gh
ts
 (m
g)
Melagatran (mg/kg) Rivaroxaban (mg/kg)
 
Dabigatran 
60 
 
Antithrombotic effect of ER-410660 in the photochemically-induced arterial 
thrombosis rat model 
The antithrombotic effect of ER-410660 in the photochemically-induced arterial 
thrombosis rat model is shown in Fig. 7A. ER-410660 caused a dose-dependent 
prolongation of TTO from 11.4 ± 1.7 min following vehicle administration to 16.8 ± 2.5, 
23.5 ± 2.5, and 27.9 ± 1.6 min following administration of 0.3, 1, and 3 mg/kg, 
respectively. The TTO2 value was 0.99 mg/kg (95% CI, 0.51–1.9). Dabigatran and 
rivaroxaban also prolonged TTO in a dose-dependent manner, with TTO2 values of 
0.078 mg/kg (95% CI, 0.047– 0.12) and 0.34 mg/kg (95% CI, 0.24– 0.50), respectively 
(Fig. 7B). 
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Fig. 7. Effects of ER-410660, dabigatran, and rivaroxaban on time to occlusion in a 
photochemically-induced, arterial thrombosis rat model. (A) ER-410660 and (B) 
dabigatran and rivaroxaban. Results are expressed as the mean ± SEM; n = 8 
animals/group. 
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Rat ex vivo coagulation assay after intravenous administration of 
ER-410660  
Coagulation time was measured after the intravenous administration of ER-410660 to 
rats. The PT and aPTT values after administration of 1 mg/kg of ER-410660 are 
summarized in Table 9. PT was prolonged by 31%, 18%, and 11% at 1, 5, and 15 
minutes after ER-410660 administration, respectively, whereas slight aPTT changes 
were observed only at 1 min after administration. 
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Table 9: Ex vivo measurement of PT and aPTT after iv ER-410660 (1 mg/kg) 
administration in rats 
  
 
Coagulation time (sec) 
 
 Relative to pre (%) 
 
Time after in administration (min) 
 
 Time after in administration (min) 
  Pre 1 5 15   1 5 15 
PT 10.1 ± 0.2 13.2 ± 0.3 11.9 ± 0.2 11.2 ± 0.3 
 
131 ± 1 118 ± 3 111 ± 3 
aPTT 10.8 ± 0.2 12.3 ± 0.4 11.4 ± 0.2 11.1 ± 0.4   113 ± 1 105 ± 1 103 ± 1 
Results are expressed as the mean ± SEM; n = 3 animals. 
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Effect of ER-410660 on bleeding time in the tail-cut model in rats 
Since the bleeding time did not differ from the baseline value following intravenous 
administration of < 1 mg/kg of ER-410660 in the rat tail-cut model, the bleeding risk for 
ER-410660 was measured at doses (2.5, 5.0, and 7.5 mg/kg) greater than the ED50 found 
in the rat venous thrombosis model. ER-410660 increased the total bleeding time by 
approximately 1.5-, 1.6-, and 2.1-fold, respectively, in a dose-dependent manner. The 
calculated BT2 value was 7.1 mg/kg (95% CI, 6.1–11) (Fig. 8A). Dabigatran and 
rivaroxaban also increased the total bleeding time in a dose-dependent manner, with 
BT2 values of 0.053 mg/kg (95% CI, 0.041–0.071) and 0.060 mg/kg (95% CI, 0.025–
0.11), respectively (Fig. 8B).    
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(A) 
 
(B) 
 
Fig. 8. Effect of ER-410660, dabigatran, and rivaroxaban on total bleeding time in 
a rat tail-cut model. (A) ER-410660 and (B) dabigatran and rivaroxaban. Results are 
expressed as the mean ± SEM; n = 8 animals/group.  
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Inhibitory effects of the oral administration of E5539 on TF-induced 
thrombin generation 
To increase oral availability, drug-discovery efforts focused on prodrug formation 
identified E5539. The permeated E5539 from intestine was activated by carboxyl 
esterases and the ER-410660 was released to plasma. The inhibitory effects of the oral 
administration of E5539 on TF-induced, de novo thrombin generation were examined in 
rhesus monkeys, which have a VIIa structure closely resembling that of humans. PTs 
and aPTTs, after oral E5539 administration, are summarized in Table 10. Orally 
administered E5539 prolonged the PT by 16% and 22% at doses of 10 and 30 mg/kg, 
respectively; aPTT remained unchanged at all doses. Plasma TAT complex levels were 
reduced in a dose-dependent manner, and statistical significances were observed even at 
the lowest dose of 3 mg/kg (Fig. 9). The ED50 value, which is the dose that causes a 
50% reduction of vehicle control TAT levels, was 11.6 mg/kg (95% CI, 8.01−16.7) 
following oral E5539 administration. 
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Table 10: Ex vivo measurement of PT and aPTT after oral E5539 administration in 
rhesus monkey 
  
 Coagulation Time (s) 
Treatment PT aPTT 
Vehicle 15.2 ± 0.3 25.8 ± 0.8 
3 mg/kg 15.4 ± 0.5 24.9 ± 0.7 
10 mg/kg 17.6 ± 0.8 26.5 ± 0.8 
30 mg/kg 18.6 ± 0.8 26.9 ± 1.0 
 
Results are expressed as the mean ± SEM; n = 11 animals per group. 
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Fig. 9. Effects of oral administration of E5539 on TF-induced TAT complex 
formation in rhesus monkeys. Results are expressed as the mean ± SEM; n = 11 
animals/group (*p < 0.05 versus vehicle-treated group). 
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Discussion 
In the experiments examining the ex vivo coagulation time, after the intravenous 
administration of ER-410660 (1 mg/kg), the prepared plasma, 1 min after injection, 
showed a 31% prolongation of PT compared to the pre-treated plasma, and the aPTT 
was prolonged by 13%. Because aPTT is more sensitive than the PT to thrombin 
inhibitors [44], and factor XIa inhibition is theoretically affected only by aPTT, both 
thrombin and factor XIa inhibition have been suggested to cause dominant prolongation 
of aPTT. The data showed that PT was dominantly prolonged after the administration of 
1 mg/kg ER-410660 and the effectiveness in the venous thrombosis model was shown 
in less than 1 mg/kg. It was suggested that thrombin and XIa inhibition might not affect 
in the venous thrombosis models, but it was uncertain whether antithrombotic effects 
were solely by TF/VIIa inhibition or no when the rats were dosed more than 1 mg/kg or 
higher. 
ER-410660 also doubled the total bleeding time in a rat tail-cut model at a dose of 7.1 
mg/kg, which was 39-fold higher than the ED50 value in the venous thrombosis model 
and 7.2-fold higher than the TTO2 value in the arterial thrombosis model. Table 11 
summarizes the calculated bleeding risk of ER-410660, dabigatran, and rivaroxaban. 
The results show that the TF/VIIa inhibitor has the lowest bleeding propensity in the rat 
experiments compared to the approved agents that directly inhibit thrombin and factor 
Xa. The half-life of ER-410660 in rats, after intravenous administration was 1.2 h, 
compared to the 1.0-h and 0.43-h half-lives of dabigatran and rivaroxaban, respectively 
(Data not shown). Based on these data, the pharmacokinetic differences did not increase 
the margin of ER-410660 for bleeding. 
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Table 11: Summary of in vivo experiments and calculated safety margin of 
ER-410660, dabigatran, and rivaroxaban against bleeding in rats 
  
  
  
ER-410660 Dabigatran Rivaroxaban 
Venous thrombosis                 
ED50 
0.18 mg/kg 0.0033 mg/kg 0.074 mg/kg 
Arterial thrombosis                                  
TTO2 
0.99 mg/kg 0.078 mg/kg 0.34 mg/kg 
Tail-cut                                 
BT2 
  
7.1 mg/kg 0.053 mg/kg 0.060 mg/kg 
Margin 1 
(BT2/ED50) 
39 16 0.81 
Margin 2 
(TTO2/ED50) 
  
7.2 0.68 0.18 
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Orally administered E5539, a prodrug form of ER-410660, also inhibited TF-induced, 
de novo thrombin generation in a rhesus monkey model with an ED50 value of 11.6 
mg/kg and reduced the plasma TAT complex levels that were elevated by TF-injection. 
Ex vivo coagulation tests showed that the PT for the E5539-administered group (10 
mg/kg) was prolonged by 16% compared to that for the vehicle-treated group. In 
contrast, no changes in aPTT were detected at any E5539 dose. Pharmacological 
activity has not been previously described in non-human primates for an orally available 
TF/VIIa inhibitor. Thus, E5539 will promote the development of novel oral 
anticoagulants that may act as preventive agents for several thrombotic conditions, 
without also enhancing the risk of bleeding.  
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CHAPTER V: Discussion 
The increased risk of bleeding is a serious complication for almost all antiplatelet, 
anticoagulant, and fibrinolytic drugs. Direct thrombin and factor Xa inhibitors have an 
antithrombotic effect, however, their efficacies are associated with a substantial increase 
in bleeding propensity [14−19]. TF/VIIa complex is known to produce factor IXa at 
approximately the same rate as factor Xa when both the substrates are present [24]. 
Thus, sequential activation of coagulation factors IX and X by proteolysis results in an 
initiation of extrinsic coagulation. This produces an agents that can regulate the 
cascade’s initiation phase by inhibiting TF/VIIa complex that could preserve the 
intrinsic coagulation pathway, thereby decreasing the bleeding risk. Studies using 
recombinant VIIa and anti-TF antibody have shown that undesirable changes in 
hemostatic function, such as bleeding, were not observed in clinical trials, except for the 
expected prolonging of PT [25,26].  
Another recent study has shown that direct inhibition of the TF/FVIIa catalytic 
complex by recombinant nematode anticoagulant protein c2 (rNAPc2) administered 
within 1 hour of surgery at a dosage of 3.0 μg/kg yielded the lowest overall venous 
thrombosis rates with no significant increase in bleeding [27]. These findings were the 
first evidence, in humans, that a TF/VIIa inhibitor was efficacious for the prevention of 
venous thrombosis. These findings are the first evidence in humans that a TF/FVIIa 
inhibitor is efficacious for prevention of venous thrombosis, providing confirmation that 
suppression of the extrinsic coagulation pathway, which is triggered by TF expression, 
could be used for prevention of thrombotic events. In this previous study, PT was 
approximately twice the length of the that observed in the placebo-treated group, while 
no significant change in the coagulation time of aPTT was observed [27]. These results 
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indicate that PT should be established as a pharmacodynamics marker, which will allow 
selection of a suitable clinical dose for agents that selectively inhibit the TF/FVIIa 
complex. 
In the present study, ER-410660 was identified as a potent and selective enzyme 
inhibitor of the TF/VIIa complex and E5539 as an orally available prodrug form. 
ER-41066 surely prolongs the extrinsic coagulation pathway and has less 
anticoagulation efficacy against the intrinsic pathway. ER-410660 showed a greater 
margin between the BT2 in the rat tail-cut bleeding model and the ED50 in the venous 
thrombosis model or the TTO2 in the arterial thrombosis model, indicating that the 
bleeding risk associated with this TF/VIIa inhibitor is much smaller than that of 
currently marketed drugs, such as direct thrombin and Xa inhibitors. Moreover, in a 
series of synthesized compounds, I found that the in vivo BT2 and ED50 margins were 
positively correlated with the selectivity of the anti-coagulation effect on PT [Hirota S et 
al., 242nd ACS National Meeting]. Taken together, these data further support the 
attractiveness of a TF/VIIa inhibitor for use as an antithrombotic drug.  
Recently, the efficacy and safety of new-generation, oral anticoagulant agents were 
compared with placebo in patients receiving antiplatelet therapy after acute coronary 
syndrome (ACS). The pooled results showed that the use of thrombin or Xa inhibitors 
moderately reduced the risk for stent thrombosis or composite ischemic events, without 
a significant effect on overall mortality. However, the thrombin and Xa inhibitors were 
also associated with a dramatic increase in major bleeding events, and treatment with 
new-generation oral anticoagulant agents did not provide any advantage over placebo 
on the net clinical benefit [45]. Due to our finding of a low bleeding risk associated with 
TF/VIIa inhibition, I speculate that targeting the TF/VIIa complex may be a superior 
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approach for the treatment of not only venous thrombosis, but also atherothrombotic 
diseases.  
The bleeding risk associated TF/VIIa inhibitor should be investigated more 
thoroughly given that data from gene knockout studies, in mice, have shown that TF, as 
well as factor VII, factor X, and prothrombin, are essential for hemostasis and 
embryonic development [46]. Mice that express low levels of TF (low-TF) and low 
levels of murine factor VII (low-FVII) showed fatal hemorrhaging in the brain, lung, 
intestine, and uterus. Both types of mice also exhibited hemosiderin deposition and 
fibrosis in the hearts [5, 47]. In addition, Snyder et al. reported that the administration of 
human TF monoclonal antibody to human TF knock-in mice caused tissue-specific 
hemorrhaging in the brain, heart, lung, and testis [48]. Humans with factor VII 
deficiency are found at a low frequency (1 in 500,000) and these patients experience 
intra-articular and mucocutaneous bleeding, analogous to patients with hemophilia A or 
B [49]. Moreover, severe factor VII deficiency is associated with cerebral hemorrhage 
and perinatal death [50]. On the other hand, a 7-day intravenous administration 
(ER-410660 at 25 mg/kg) study in rats showed that critical hemorrhaging and 
abnormalities were not evident in clinical pathology (Data not shown). Thus, the actual 
bleeding risk of TF/VIIa inhibitors should be elucidated in a future clinical trial. 
In addition to its primary role as an initiator of coagulation, the TF/VIIa complex is 
also known to influence protease-activated, receptor-dependent tumor cell behaviors, 
such as proliferation, metastasis, and angiogenesis, suggesting that TF may also 
determine tumor progression. A strong correlation between cancer and aberrant 
hemostasis is now widely recognized, and patients with various types of cancer, 
including pancreatic, colorectal, and gastric cancers often develop thrombosis [51]. 
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These findings underline the importance of developing orally active TF/VIIa inhibitors, 
not only to prevent venous thrombosis and other TF-mediated diseases, including 
arterial thrombotic events, intracardiac thrombus formation, sickle cell anemia, and 
inflammatory disorders [46], but also for their potential use as oncology-related drugs 
[46,49]. Having both parenteral and orally available forms of at least one TF/VIIa 
inhibitor will facilitate the design of specific anti-thrombotic and anti-cancer treatments.  
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